Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183833 · ClinicalTrials.gov registry record · Phase 1
Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00183833 is a Phase 1 study that has completed, run by University of Southern California. The registered enrollment target is 40 participants.
The verdict
NCT00183833, a Phase 1 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is for people with solid tumors cancer for which the standard chemotherapy drugs have not worked. The purpose of this research is to evaluate the side effects of Xeloda (also called capecitabine) in combination with a new anticancer agent called Gleevec (also called imatinib mesylate). Xeloda is an anticancer drug, and can be taken by mouth. The active ingredient is a well-studied cancer drug called 5-FU. Xeloda is approved by the FDA for the treatment of colon cancer. Gleevec is approved in the US for the treatment of patients with a leukemia called CML (increase of white blood cells) after failure of standard therapy. It is also approved by the FDA for patients with Gastrointestinal Stromal Tumors (a rare tumor in the digestive tract). This study will test how much Gleevec we can safely give with Xeloda. Xeloda will be given at the recommended dose for colorectal cancer and Gleevec will be given in increasing amounts.
Interventions
- DRUG capecitabine, imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183833
The ClinicalTrials.gov registry entry for NCT00183833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which capecitabine, imatinib mesylate is the first listed.
NCT00183833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183833 about?
NCT00183833 is a clinical study titled "Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors". This study is for people with solid tumors cancer for which the standard chemotherapy drugs have not worked. The purpose of this research is to evaluate the side effects of Xeloda (also called capecitabine) in combination with a new anticancer agent called Gleevec (also called imatinib mesylate). Xe...
What is the current status of trial NCT00183833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2002-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00183833?
The interventions under investigation include: capecitabine, imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00183833?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.